Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 12/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.39 |
| ▸ | HTR2A | P28223 | 3/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | ACACB | O00763 | 5/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5114884 | 0.79 | MCHR1 (0.43) | MCHR1CHRM1HTR2ACYP2D6ACACB | |
| SCHEMBL5198628 | 0.71 | MCHR1 (0.48) | MCHR1CHRM1HTR2ACYP2D6ACACB | |
| SCHEMBL2324867 | 0.70 | MCHR1 (0.59) | MCHR1CHRM1HTR2ACYP2D6 | |
| SCHEMBL4493107 | 0.69 | MCHR1 (0.51) | MCHR1CHRM1HTR2ACYP2D6ACACB | |
| SCHEMBL4493104 | 0.65 | MCHR1 (0.58) | MCHR1CHRM1HTR2ACYP2D6 | |
| SCHEMBL4529404 | 0.65 | MCHR1 (0.51) | MCHR1CHRM1HTR2ACYP2D6ACACB | |
| SCHEMBL2322150 | 0.64 | MCHR1 (0.64) | MCHR1CHRM1HTR2ACYP2D6 | |
| SCHEMBL4483261 | 0.64 | MCHR1 (0.45) | MCHR1CHRM1HTR2ACYP2D6ACACB | |
| SCHEMBL6364847 | 0.63 | MCHR1 (0.44) | MCHR1CHRM1HTR2ACYP2D6ACACB | |
| SCHEMBL6364854 | 0.63 | MCHR1 (0.44) | MCHR1CHRM1HTR2ACYP2D6ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7452911-B2 | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2008-11-18 | — | — | US | disclosed |
| US-20040209865-A1 | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209865-A1 | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds | MCHR1, MCHR2, NPY1R | MCHR1 1/4885CHRM1 62/4885HTR2A 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.